Summary. The receptors mediating the contractile effect of 5-hydroxytryptamine (5-HT) on the human isolated saphenous vein, obtained from 42 patients undergoing coronary bypass surgery, have been further characterized using a number of 5-HT-related drugs. The rank order of agonist potency was 5-carboxamidotryptamine (5-CT) 5-HT > methysergide ~ sumatriptan ~ c~-methyl-5-HT ~ 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-lHindolesuccinate (RU 24969) ~ 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI) > 2-methyl-5-HT > 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT). Flesinoxan was inactive as an agonist. Ketanserin (1 gmol/1) hardly affected sumatriptan-induced contractions but it caused a rightward shift of the upper part of the concentration-response curve of 5-HT and 5-CT. The same concentration of ketanserin caused a parallel rightward shift of the concentration-response curves of c~-methyl-5-HT and DOI with pKB values of 7.1 and 7.1, respectively. The responses to sumatriptan were antagonized by methiothepin (0.1 gmol/1), metergoline (0.1 and 1 gmol/1), rauwolscine (1 lamol/1) and cyanopindolol (1 gmol/1); the calculated pKB values were 7.3, 6.9, 7.3, 6.7 and 6.5, respectively. Contractions to 5-HT were antagonized by methysergide (1 gmol/1), methiothepin (0.1 ~tmol/1; pKB=7.1), ICS 205-930 (1 lamol/1; pKB = 5.9) and flesinoxan (30 gmol/1; pKB = 5.3). Remarkably, the contractions elicited by 2-methyl-5-HT were not attenuated by ICS 205-930, but were antagonized by methiothepin (0.1 gmol/1) and, more markedly, by ketanserin (1 gmol/1).
Introduction
Saphenous vein and internal mammary artery are frequently used as a graft in coronary bypass operations. Several differences between these two vessels have been found that could possibly account for the superior patency of mammary artery grafts (Loop et al. 1986; Liischer et al. 1988) . Recently, Yang et al. (1991) reported that, when precontracted with noradrenaline, the human isolated saphenous vein contracts but the human isolated internal mammary artery relaxes to platelets. Plateletderived ADP caused the mammary artery to relax while contractions in the saphenous vein were shown to be mediated by thromboxane A2 and 5-HT. The 5-HT-induced saphenous vein contractions are sensitive to ketanserin and spiperone, both 5-HT2 receptor antago- 
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methyl-5-HT; A, DOI; ~, 2-methyl-5-HT and 4-, methysergide. Agonist concentration refers to mol/1. Emax and pD2 as well as the number of segments tested are mentioned in Table I nists. This ketanserin-sensitive receptor is activated mainly at high concentrations of 5-HT, while lower concentrations seem to activate a yohimbine-and methiothepin-sensitive 5-HT receptor (Docherty and Hyland 1986; Victorzon et al. 1986; Chester et al. 1990a; Docherty and Borton 1991) . The present study was undertaken to further characterize the 5-HT receptors mediating contractions in the human saphenous vein. In addition, we also had the opportunity to compare the responses mediated by 5-HT receptors in the vessels which had functioned as coronary bypass grafts for a number of years. A part of the results of this investigation was presented to the British Pharmacological Society (Bax et al. 1992 ).
Methods
Tissue preparation. Leftover The concentration-response curve did not achieve a plateau even at the highest concentrations studied (10 -4 tool/l) n, Number of observations
In addition, saphenous vein could also be obtained from three male patients (aged 46, 48 and 61 years) with progressive ischemic heart disease, undergoing cardiac transplantation. These patients had previously undergone coronary bypass surgery where saphenous vein had been used as a graft for a period of 6, 7 and 11 years, respectively, prior to transplantation. The vein was collected from these hearts within 45 min of cardiectomy.
The vessels were cut into rings of approximately 4-5 mm of length and suspended on stainless steel hooks in 8 ml organ baths containing the Krebs' bicarbonate solution, aerated with 95% 02 and 5% CO2 and maintained at 37°C. The tissues were allowed to equilibrate for at least 30 min and washed every 10 min. Changes in isometric tension were recorded with a Harvard isometric transducer. Preparations were then stretched to the optimum point of the length-tension relation, as determined by tension developed to 30 mmol/1 K ÷. The rings were left to equilibrate for another 30 min after which the actual experiment began. Endothelial integrity was not assessed in these experiments, since the presence of endothelium does not influence 5-HT-induced contractions in this vessel (Yang et al. 1989 ).
Determination of agonist potency.
A cumulative concentration-response curve to 5-HT was obtained on each preparation until a maximum response (Emax) was obtained. After frequent washing the tissue was left to equilibrate for at least 30 min. When the baseline tone was reached, the tissue was exposed to either 5-HT again or to another test agonist. In each vessel segment, the second 5-HT concentration-response curve or the only concentration-response curve to the other agonists was expressed as percentage of the Emax of the first 5-HT curve.
To determine agonist potency in saphenous vein grafts that had been in situ for some years, a single concentration effect curve was obtained with either 5-HT or sumatriptan. These responses were expressed as a percentage of potassium (30mmol/1)-induced contractions in the grafted veins. The response to potassium (30 mmot/1), and the Ema x and pD2 values (see below) of 5-HT and sumatriptan were compared to the respective contraction or curves in the ungrafted saphenous veins.
Determination of antagonist potency.
A concentration-response curve to 5-HT was made and the preparation was washed as described above. About 30 rain later, a second cumulative concentration-response curve was obtained with either 5-HT or another agonist, without or after incubation (30 rain) with a certain concentration of an antagonist. The second curve without antagonist, mostly obtained in parallel, served as a control for the curve in the presence of antagonists. Table 2 Analysis of data. All curves were analyzed by means of a computerized curve fitting technique (De Lean et al. 1978 ) to obtain Ema x (maximal response) and pD 2 (-Log of the molar concentration of an agonist eliciting half maximal effect) values, which were averaged for the respective agonists. For antagonists approximate pKB values were calculated, assuming the nature of antagonism to be competitive, by the equation described by Furchgott (1972) :
where [B] is the antagonist concentration and [A1] and [A2] are, respectively, the equi-effective molar concentrations of the agonist needed to elicit half maximal effect in the absence and presence of [B] . For calculation of pK~ values only paired experiments were taken into account, unless mentioned otherwise. All data are presented as mean +_ SEM. For correlation the Pearson correlation coefficient was calculated. To test the hypothesis of a straight line underlying the points in Fig. 5 , lack of fit statistics (Kleinbaum et al. 1988 ) was performed using ~ = 0.05 as a critical value. Student's t-test for unpaired data was used for comparison of mean values. A p-value of < 0.05 was assumed to denote a significant difference.
Compounds. The following drugs were used in this study: 5-carboxamidotryptamine maleate (5-CT; gift: Glaxo, Ware, UK), cyanopindolol (gift: Sandoz AG, Basel, Switzerland), l-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane hydrochloride (DOI; Research Biochemicals Inc., Natic, Ma, USA), flesinoxan hydrochloride (gift: Duphar B. V., Weesp, The Netherlands), 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT; gift: Merrel Dow Research Institute, Strassbourg, France), 5-hydroxytryptamine creatinine sulphate (5-HT; Sigma Chemical Co., St. Louis, Mo., USA), 3c~-tropanyl-IH-indole-3-carboxylate (ICS 205-930; gift: Sandoz AG, Basel, Switzerland), ketanserin tartrate (gift: Janssen Pharmaceutica, Beerse, Belgium), metergoline (gift: Farmitalia, Milan, Italy), methiothepin maleate (gift: Hoffmann-La Roche B. V., Mijdrecht, The Netherlands), 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole succinate (RU 24969; gift: Roussel Laboratories, Hoevelaken, The Netherlands), 2-methyl-5-hydroxytryptamine maleate (2-methyl-5-HT; gift: Glaxo, Ware, UK), a-methyl-5-hydroxytryptamine maleate (~-methyt-5-HT; gift: Glaxo, Ware, UK), rauwolscine hydrochloride (Fluka AG, Buchs, Switzerland) and sumatriptan (gift: Glaxo, Ware, UK). We appreciate the generosity of the companies in providing the compounds.
Results

Effect of agonists
The concentration-response curves obtained on the human isolated saphenous vein with the different agonists and the derived values of pD2 and Emax are shown in Fig. 1 and Table 1 , respectively. It is to be noted that contractions in the second 5-HT concentration-response curve were only slightly less than in the first 5-HT curve. All other agonists, except flesinoxan, were found to contract the saphenous vein in a concentration dependent manner, but only 5-CT and e-methyl-5-HT acted as a full Table 3 , unpaired experiments are displayed also agonist. The rank order of potency was: 5-CT ~ 5-HT > methysergide ~ sumatriptan ~ c~-methyl-5-HT RU 24969 ~ DOI > 2-methyl-5-HT > 8-OH-DPAT.
As shown in Table 2 , the exposure to potassium (30 mmol/1) caused contractions of the saphenous veins that had been used as a graft, but the tension generated in these vessels was only about 10% of that observed in the non-grafted veins. Though the responses to both 5-HT and sumatriptan in the grafted vessels were also diminished, the respective Ema x values, when expressed as a percentage of potassium (30 mmol/1)-induced contraction, as well as the pD2 values were similar to those in the non-grafted veins (Table 2; Fig. 2) .
Effect of antagonists
The effects of ketanserin (1 pmol/1), methiothepin (0.1 gmol/1), methysergide (1 pmol/1), flesinoxan (30 gmol/1) and ICS 205-930 (1 gmol/1) were studied against the responses to at least one of the following agonists: 5-HT, 5-CT, RU 24969, c~-methyl-5-HT, DOI and 2-methyl-5-HT (Fig. 3) . The calculated approximate pKB values are shown in Table 3 . The responses to 5-HT were antagonized by methysergide, ketanserin and methiothepin (pK B = 7.1 _ 0.4), but also to some extent by ICS 205-930 (pKR = 5.9 + 0.1) and flesinoxan (pKB = 5.3 + 0.2). The pKB values for methysergide (concentration-response curve did not reach plateau) and ketanserin (biphasic concentration-response curve) were not calculated (see Table 3 ). The antagonism by ketanserin was more marked against contractions due to higher concentrations of 5-HT. The effects of low concentrations of 5-CT were little affected by ketanserin (1 gmol/1) or methiothepin (0.1 gmol/1), but those of high concentrations (_>0.1 gmol/1) were attenuated by both methiothepin and ketanserin. The contractile effects of RU 24969 were antagonized by methiothepin (0.1 ~tmol/ 1). Contractions to c~-methyl-5-HT and DOI were attenuated by ketanserin (1 gmol/1), while those to 2-methyl-5-HT, being unaffected by ICS 205-930, were antagonized by methiothepin (0.1 ~tmol/1) and, even more potently, by ketanserin (1 gmol/1). Figure 4 shows the effects of methiothepin (0.1 pmol/1), metergoline (0.1 and 1 gmol/1), ketanserin (1 gmol/1), cyanopindolol (1 gmol/1) and rauwolscine (1 gmol/1) on the responses to sumatriptan. The sumatriptan-induced contractions remained unaffected by ketanserin, but methiothepin, metergoline, cyanopindolol and rauwolscine behaved as antagonists ( Fig. 4; Table 3 ). Table 3 . In cases where onists (0.1 gmol/1, • and 1 gmol/1, •). Agonist concentration refers the number of experiments mentioned here does not correspond to to mol/1. Number of segments tested: control, 18; methiothepin, 8; the number mentioned in Table 3 , unpaired experiments are disketanserin, 8; metergoline (1 gmol/1), 7; metergoline (0.1 gmol/1), played also
Discussion
Previous studies (Docherty and Hyland 1986; Victorzon et al. 1986; Borton and Docherty 1988; Chester et al. 1990a; Docherty and Borton 1991) in the human isolated saphenous vein have revealed that 5-HT-induced contractions were: (i) partially antagonized by spiperone and ketanserin, both of which preferentially affected the contractions following high concentrations of 5-HT; and (ii) mimicked by 5-CT, sumatriptan, RU 24969, c~-methyl-5-HT, 5-methoxytryptamine and 8-OH-DPAT. Since contractions to e-methyl-5-HT and high concentrations of 5-HT were antagonized by ketanserin and since the effect of sumatriptan was antagonized by methiothepin but not markedly by ketanserin, both 5-HTl-like and 5-HT2 receptors seem to be present in the human saphenous vein (Docherty and Hyland 1986; Borton and Docherty 1988; Chester et al. 1990a) .
The frame-work of 5-HT receptor classification, originally proposed by Bradley et al. (1986) , has now been expanded (Dumuis et al. 1988 ) and currently four main types of 5-HT receptors (5-HT~-like, 5-HT2, 5-HT3 and 5-HT4) are recognized (see Saxena and Villal6n 1990) . It is well established that the 5-HTl-like receptor category is heterogeneous in nature (5-HTaA, 5-HT~B, 5-HTac and 5-HTaD) and even this subdivision seemingly does not completely correspond to the functional responses observed (Saxena and Ferrari 1989; Saxena and Villal6n 1990; Van Heuven-Nolsen et al. 1991) . It is with this background that we have attempted to further characterize the human saphenous vein 5-HT receptors by using a large number of 5-HT receptor agonists and antagonists.
Identification of the 5-HT receptors
The presence of a contractile 5-HTl-like receptor in the human saphenous vein is revealed by the fact that: (i) 5-CT, sumatriptan, RU 24969 and 8-OH-DPAT, all of which have more or less selective agonist action at 5-HT~-like receptors, elicited saphenous vein contractions; (ii) the contractions elicited by sumatriptan were resistant to blockade by ketanserin, but were antagonized by methiothepin and other compounds with affinities for 5-HT1 binding sites (metergoline, cyanopindolol and rauwolscine); and (iii) methiothepin clearly antagonized the responses to RU 24969. It should, however, be noted that the putative 5-HT1A receptor agonist flesinoxan (Wouters et al. 1988; Dreteler et al. 1990 ) did not behave as an agonist, but rather as a weak antagonist of the responses to 5-HT; such an antagonist effect of flesinoxan has been described at the 5-HT l-like receptor in the rabbit saphenous vein (Martin and MacLennan 1990) . Lastly, despite the above evidence for the presence of 5-HTl-like receptors in the saphenous vein, we have no adequate explanation why methiothepin, in contrast to its interaction with sumatriptan and RU 24969, did not cause a parallel shift of the lower part of the concentration-response curve of 5-CT. Possibly 5-CT acts as an agonist on other receptors than the 5-HTl-like receptor present in this vessel; the antagonism by ketanserin of the upper part of the 5-CT-curve indicates that 5-CT activates 5-T2 receptors, especially at high concentrations. This phenomenon has been observed before in the human coronary artery (Toda and Okamura 1990 ) and the rabbit aorta (Feniuk et al. 1985) .
Our experiments also provide evidence in favour of 5-HT2 receptor-mediated contractions of the human saphenous vein. Thus, the contractile effects of 5-HT were antagonized by ketanserin in a clearly biphasic manner, mainly affecting the higher concentrations of 5-HT. Moreover, the relatively selective 5-HT2 receptor agonist DOI, as well as c~-methyl-5-HT, caused concentrationdependent saphenous vein contractions that were also antagonized by ketanserin (Fig. 3) . The calculated pKB values (7.1 against both 5-HT2 receptor agonists) are admittedly somewhat low compared to those in other tissues (Conti et al. 1990; Mylecharane 1991) . It is, however, possible that the blocking activity of ketanserin is being underestimated because, certainly, c~-methyl-5-HT has appreciable binding as well as functional affinity for 5-HT~ receptor subtypes (Humphrey et al. 1990; Ismaiel et al. 1990; Mylecharane 1991) . The presence of both 5-HTa-like and 5-HTz receptors in the saphenous vein is further strengthened by the nature of the effects of methiothepin and methysergide; these mixed 5-HTx-like and 5-HTz receptor antagonists shifted the concentration-response curve of 5-HT in a near parallel manner.
We would like to draw attention to three other findings in our present investigation. Firstly, as found earlier, particularly at 5-HT~-like receptors (Saxena 1974; Saxena and Villal6n 1990) , methysergide had a partial agonist action weakly contracting the saphenous vein. Secondly, 2-methyl-5-HT contracted the human saphenous vein (Fig. 3) . Since this compound is generally considered selective for the 5-HT3 receptor (Bradley et al. 1986; Saxena and Villaldn 1990) , it may be argued that 5-HT3 receptors also mediate contraction in this tissue. However, as also recently found in the rabbit isolated renal artery (Tadipatri and Saxena 1992) , the contractions elicited by 2-methyl-5-HT were not attenuated (perhaps somewhat potentiated) by ICS 205-930. The low pD2 value of 2-methyl-5-HT (4.8 __ 0.2) and the antagonism of its effects by methiothepin and, particularly, ketanserin strongly suggests that 2-methyl-5-HT contracted the human saphenous vein via 5-HT2 receptors. However, in view of the tenfold higher affinity of 2-methyl-5-HT for the 5-HT1 receptor subtypes than for the 5-HT2 receptor (Hoyer 1989; Ismaiel et al. 1990) , an additional involvement of 5-HTl-like receptors can not be excluded. Thirdly, in the absence of 5-HT3 receptors, the ability of ICS 205-930 (1 lamol/1) to weakly attenuate 5-HT-induced contractions may point to the existence of 5-HT4 receptors in the human saphenous vein. On the other hand, though present in the brain (Dumuis et al. 1988 ), heart (Duncker et al. 1985; Kaumann et al. 1990; Villal6n et al. 1990 ) and gastro-intestinal system (Clarke et al. 1989 ), the 5-HT4 receptors have not yet been located in blood vessels.
Is the 5-HTx-like receptor related to 5-HTt binding site subtypes?
Since receptor binding experiments clearly distinguish at least four 5-HT1 binding site subtypes (5-HT1A, 5-HT1B, 5-HT 1 c and 5-HT 1 D) (see Waeber et al. 1988; Hoyer 1989; Schoeffter and Hoyer 1989) , we have compared agonist pD2 and antagonist pKB values obtained in the present experiments with the binding affinities at the above 5-HT1 binding subtypes (Fig. 5) . Admittedly, such a comparison is slightly hampered by the fact that we deal with two different receptor populations (5-HT~-like and 5-HT2) in the saphenous vein. In order to counter this potential disadvantage, we chose agonists (including 5-HT) with a relatively high affinity for 5-HT~-like receptors and the pKB values of antagonists against the selective 5-HT~-like receptor agonist sumatriptan. The above comparison yielded the following correlation coefficients (r): 0.12, 0.74, 0.40, 0.97 and 0.98 for the agonists; and 0. 65, 0.45, 0.21, 0.77 and 0.89 for the antagonists at, respectively, 5-HT1A, 5-HT1B, 5-HTlc, 5-HT1D, (calfcaudate) and 5-HT~D (human caudate) receptors. The correlation at the 5-HT1A, 5-HT1B and 5-HTlc was not only lower than that at the 5-HTm receptors (both in the human and calf caudate membranes), but also a theoretical straight line connecting the correlation points (see Fig. 5 ) for these three 5-HTI binding subtypes (but not for agonists at 5-HTID) could be rejected (c~=0.05). Therefore, the 5-HT l-like receptor mediating contraction of the human isolated saphenous vein resembles the 5-HTm receptor subtype, a conclusion that is also supported by data reported earlier (Miiller-Schweinitzer 1984; Docherty and Borton 1991) . However, this receptor may not be entirely indentical to the 5-HTxD receptor identified in the calf or human caudate membranes, since the order of binding affinity at the 5-HT1D receptor site of methiothepin and metergoline is contradictory to the potency order of functional antagonism against sumatriptan. An analogue observation was made by Hamel and Bouchard (1991) for the 5-HT1D receptor contracting the human isolated pial arteries. Indeed, Sumner and Humphrey (1989) have already proposed a subdivision for 5-HTm receptors, and the primary structure and function of the cloned 5-HT1D receptor (Hamblin and Metcalf 1991) shows several marked discrepancies with the published 5-HTID receptor affinities (Waeber et al. 1988) .
Comparison between and grafted saphenous veins
Apart from a recent solitary report on a 12-year old saphenous vein graft (Steen et al. 1991) , we are not aware of any other pharmacologic investigations comparing such vessels. As also observed by us in the microscopic (Tables 1 and  3 ) and pKD (expressed as -Log mol/1) values for 5-HT1 binding site subtypes. All binding data are from Hoyer (1989) , except those for sumatriptan (Schoeffter and Hoyer 1989 ) and for 5-HTto binding in the human caudate membrane (Waeber et al. 1988 sections (results not shown), Steen et al. (1991) found a marked proliferation of intimal layers. Their pharmacological findings, restricted to c~-adrenoceptors, indicated that such receptors mediating contraction of this grafted venous segment were 'atypical' in nature. However, with regard to 5-HT receptors, we observed no obvious change in the three grafted vessel segments studied by us; the pD2 values as well as the maximal effects of 5-HT and sumatriptan, expressed as a percentage of potassiuminduced contractions, were not different from those in the ungrafted saphenous veins. But, it appears that the general ability to contract, as indicated by the contractions to potassium (Table 2) , was substantially less in the grafted vessels. In contrast, in animal experimental venous grafts, others have reported hyper-reactivity to 5-HT, which correlated with intimal thickening (Radic et al. 1991 ; Farm et al. 1990 ). However, it has to be kept in mind that we have only had the opportunity to study grafted saphenous veins from three patients, and that patients undergoing heart transplantation have apparently a more extensive pathological lesion than those undergoing coronary bypass surgery.
Comparison with 5-HT receptors in other human vessels
Extensive studies characterizing 5-HT receptors in the human basilar (Parsons et al. 1989 ) and pial (Hamel and Bouchard 1991) arteries have been performed. Some important differences between the results obtained here and those reported earlier may be pointed out. Firstly, in the basilar and pial arteries 5-HT-induced contractions were unaffected by ketanserin, indicating the absence of 5-HT2 receptors. Secondly, unlike our experiments, 2-methyl-5-HT was ineffective in the basilar artery; however, despite the fact that contractile 5-HT3 and 5-HTz receptors are absent, pial arteries did contract to 2-methyl-5-HT, presumably via a 5-HTl-like mechanism. Thirdly, (-t-)-cyanopindolol did not affect sumatriptaninduced contractions in the basilar artery, but the concentrations used were ten times lower (0.1 gmol/1) than in our experiments. Lastly, the affinity for methiothepin was higher in the basilar (pKB: 8.8) or pial (pA2 : 8.55) arteries than in our experiments (pKB: approximately 7.1). It is possible that the 5-HTl-like receptor subtype present in the saphenous vein may not be identical with that present in the basilar arteries. However, as in the present experiments, a high correlation was found between the functional pD2 values in the pial arteries and the pKD values for the 5-HT1D binding sites in the human caudate membranes (Hamel and Bouchard 1991) . Like in the saphenous vein, both 5-HTl-like and 5-HT2 receptors have been reported in the human coronary artery and similar pD2 values for sumatriptan, 5-HT and 5-CT have been found Chester et al. 1990b; Toda and Okamura 1990) . However, at present not enough experimental data in human isolated coronary artery is available to make a valid comparison between the 5-HTl-like receptor subtype contracting coronary artery and saphenous vein.
In conclusion, a mixed population of 5-HTl-like and 5-HT2 receptors is present in the human isolated saphenous vein. Low concentrations of 5-HT contract the vessel mainly via the 5-HTl-like receptor, but at higher concentrations 5-HT2 receptors are also recruited. The 5-HT l-like receptor in the saphenous vein closely resembles the 5-HT1D subtype. These results imply that, should 5-HT be involved in the pathophysiology, 5-HT2 receptor antagonists, such as ketanserin, would not be entirely effective in preventing peri-or postoperative spasm of the saphenous vein graft. Since the human coronary vessels also contain 5-HTl-like and 5-HT2 receptors, the use of a mixed 5-HTI-like/5-HT2 receptor antagonist may well be more efficacious in ameliorating coronary artery or saphenous vein graft spasm.
